Difference between revisions of "Uveal melanoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 83: Line 83:
 
===References===
 
===References===
 
# '''EORTC 18021:''' Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol. 2014 Mar;25(3):742-6. Epub 2014 Feb 7. [https://academic.oup.com/annonc/article/25/3/742/149384 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433517/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24510314 PubMed]
 
# '''EORTC 18021:''' Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol. 2014 Mar;25(3):742-6. Epub 2014 Feb 7. [https://academic.oup.com/annonc/article/25/3/742/149384 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433517/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24510314 PubMed]
 +
 +
==TACE {{#subobject:f96a1b|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
TACE: '''<u>T</u>'''rans-'''<u>A</u>'''rterial '''<u>C</u>'''hemo-'''<u>E</u>'''mbolization
 +
===Regimen {{#subobject:93050b|Variant=1}}===
 +
{| class="wikitable" style="width: 100%; text-align:center;"
 +
!style="width: 50%"|Study
 +
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://jamanetwork.com/journals/jama/article-abstract/373516 Mavligit et al. 1988]
 +
| style="background-color:#91cf61" |Non-randomized
 +
|-
 +
|}
 +
====Chemotherapy====
 +
*[[TACE]]
 +
 +
'''1 or more treatments'''
 +
 +
===References===
 +
# Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988 Aug 19;260(7):974-6. [https://jamanetwork.com/journals/jama/article-abstract/373516 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3398202 PubMed]
  
 
[[Category:Uveal melanoma regimens]]
 
[[Category:Uveal melanoma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Skin cancers]]
 
[[Category:Skin cancers]]

Revision as of 03:13, 31 December 2018

Page editor Section editor
Matthew J. Rioth MD, MS
Denver, CO
Bethbuchbinder.jpg
 Elizabeth Buchbinder, MD
Boston, MA
LinkedIn

Note: this page is for regimens specific to uveal melanoma; see the main melanoma page for other regimens.

13 regimens on this page
13 variants on this page


Guidelines

NCCN

Metastatic or unresectable disease

Dacarbazine monotherapy

back to top

Regimen

Study Evidence Comparator Efficacy
Carvajal et al. 2014 Randomized Phase II (C) Selumetinib Might have inferior OS
Carvajal et al. 2018 (SUMIT) Phase III (C) Dacarbazine & Selumetinib Seems not superior

Chemotherapy

21-day cycles

References

  1. Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Jun 18;311(23):2397-405. link to original article link to PMC article PubMed
  2. SUMIT: Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018 Apr 20;36(12):1232-1239. Epub 2018 Mar 12. link to original article contains verified protocol PubMed

Fotemustine monotherapy

back to top

Regimen

Study Evidence Comparator Efficacy
Leyvraz et al. 2014 (EORTC 18021) Phase III (C) IHA Fotemustine Seems not superior

Chemotherapy

  • Fotemustine (Muphoran) as follows:
    • Weeks 1 to 3: 100 mg/m2 IV once per day on days 1, 8, 15
    • Weeks 4 to 8: no treatment
    • Week 9 onwards: 100 mg/m2 IV once on day 1, every 3 weeks

8-week induction cycle, then 21-day cycles

References

  1. EORTC 18021: Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol. 2014 Mar;25(3):742-6. Epub 2014 Feb 7. link to original article link to PMC article contains protocol PubMed

TACE

back to top

TACE: Trans-Arterial Chemo-Embolization

Regimen

Study Evidence
Mavligit et al. 1988 Non-randomized

Chemotherapy

1 or more treatments

References

  1. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988 Aug 19;260(7):974-6. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Uveal_melanoma&oldid=34048"